Fingolimod is known as the first oral drug that was approved by the US Food and Drug Administration to control the symptoms of multiple sclerosis (MS). By reducing the number of mature lymphocytes in the blood and central nervous system, this drug suppresses the overactive immune system and prevents the destruction of the myelin sheath wrapped around the nerve axon cells. Fingolimod is used for relapsing-remitting MS and reduces the number of attacks by reducing the access of some white blood cells to the brain and spinal cord. It also helps to slow down the progress of the patient’s physical disabilities and movement disorders.



  • Immune checkpoint inhibitors

Therapeutic class

  • Miscellaneous therapeutic agents, Biological response modulators